Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
lupus nephritis
Biotech
Kezar drops solid tumor yet to prove its worth in phase 1 trial
Kezar Life Sciences is dropping its unpromising phase 1 solid tumor drug as the biotech goes all-in on its lead autoimmune hepatitis program.
James Waldron
Aug 14, 2024 5:09am
Kyverna's CAR-T relapse in lupus dents autoimmune hopes
Jun 17, 2024 8:51am
Cullinan rebrands, halts lymphoma trial in autoimmune refocus
Apr 16, 2024 10:05am
Equillium delivers new lupus data to Ono's doorstep
Apr 1, 2024 10:53am
After hunt for buyer fails, Aurinia lays off 25%, drops R&D
Feb 15, 2024 8:25am
Kyverna overshoots raised IPO expectations with $319M offering
Feb 8, 2024 8:24am